Reuters
21 Oct 2025, 20:56 UTC · 47w ago
Verdict
Headline takes no side. We score TERN −0.90 across three claims — strongly bearish.
−0.90strongly bearish
More negative than 91% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Terns Pharmaceuticals is halting the development of its experimental obesity drug.
More negative than 99% of claims this week
A mid-stage trial for the obesity drug raised safety concerns.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 96% of claims this week
The experimental obesity drug demonstrated only modest weight loss results.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 91% of ticker scores this week
The company is halting development of its obesity drug due to modest results and safety concerns.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+552.1%
Price is moving against the score
$52.95 vs $8.12 close before publication (Oct 21) · not market-adjusted
TERN chart →
